Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis
Multiple Sclerosis, Relapsing-Remitting
Recovery of Function
In total, 3 of 22 paitents developed mild self-limited bruising associated with a drop in platelet count from their baseline during the intial 5-day course of alemtuzumab. Upon chart review, all 22 patients who received alemtuzumab developed an immediate mostly asymptomatic drop in platelet count which returned to normal within 2 months post-infusion.